Vol. XXX, n.4, 2009 ISSN: 0392-2936


european journal
of gynaecological oncology

an International Journal


Founding Editor
A. Onnis
Montréal (Canada)

Editors-in-Chief
M. Marchetti
Montréal (Canada)
P. Bösze
Budapest (Hungary)

Associate Editor
T. Maggino
Padua (Italy)

Assistant Editor
J. Wilson
San Diego - CA (USA)
Editorial Board
Allen H.H., London, Ontario (Canada)
Anteby S.O., Jerusalem (Israel)
Audet-Lapointe P., Montreal (Canada)
Ayhan A., Ankara (Turkey)
Balat O., Graziantep (Turkey)
Ba˘nceanu G., Bucarest (Romania)
Basta A., Krakow (Poland)
Bender H.C., Dusseldorf (Germany)
Benedetti Panici P.L., Rome (Italy)
Charkviani T., Tbilisi (Georgia)
De Oliveira C.F., Coimbra (Portugal)
Dexeus S. Jr., Barcelona (Spain)
Di Paola G.R.,
Buenos Aires (Argentina)
Di Re F., Milan (Italy)
Di Saia P., Orange, CA (USA)
Friedrich M., Hamburg (Germany)
Fuller A.F. Jr., Boston, MA (USA)
Geisler H.E., Indianapolis, IN (USA)
Gerbaulet A., Villejuif (France)
Gorins A., Paris (France)
Heintz A.P.M.,
Utrecht (The Netherlands)
Ioannidou-Mouzaka L.,
Athens (Greece)
Jordan J.A.,
Birmingham, England (UK)
Karseladze A.I., Moscow (Russia)
Klastersky J., Bruxelles (Belgium)
Kubista E., Vienna (Austria)
Maggino T., Padua (Italy)
Markowska J., Poznan (Poland)
Marth C., Innsbruck (Austria)
Massuger Leon F.A.G.,
Nijmegen (The Netherlands)
Menczer J., Savyon (Israel)
Monsonego J., Paris (France)
Pálfalvi L., Budapest, (Hungary)
Pinotti A., São Paulo (Brazil)
Piura B., Beer Sheva (Israel)
Piver S.M., Buffalo, NY (USA)
Rakar S., Ljubljana (Slovenia)
Raju K.S., London, England (UK)
Shepherd J.H.,
London, England (UK)
Stelmachów J., Warsaw (Poland)
Tjalma W., Antwerpen (Belgium)
Ungár L., Budapest (Hungary)
Vermorken J.B., Edegem (Belgium)
Wang P.-H., Taipei (Taiwan)
Winter R., Graz (Austria)
Yokoyama Y., Hirosaki (Japan)

Publishing Organization (M. Morsani):
I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)
Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroup-online.com - www.irog.net

Editorial Office (M. Critelli):
Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 - Fax (39) 049 8752018

 

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/ Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

 

European Journal of Gynaecological Oncology
www.irog.net


General Information

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects – prevention, early detection, epidemiology, pathology, diagnosis, management – and also proceedings of Gynaecologic Oncology Society meetings all over the world.

The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE,
EMBASE/ Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

AIMS AND SCOPE
The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing editorial articles in the “Distin-guished Expert Series” and original research papers, case reports, letters to the Editor, book reviews and newsletters.

The Journal was founded in 1980 – the second gynaecologic oncology hyperspecialization journal in the world. Its aim is the dif-fusion of scientific, clinical and practical progress and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists and so on.

ANNOUNCEMENTS regarding meetings, postgraduate courses and symposia will be accepted 6 months before publication and will be published free of charge.
BOOK SAMPLES for review should be sent to the Editorial offices in Montréal or in Padova.
COPYRIGHT: the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.
ADVERTISING INFORMATION: advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2HS, Tél. 514.4893242-4893640 - Fax 514.4854513 - E-mail: canlux@mgroup-online.com - www.irog.net
RESPONSIBILITY: although every effort is made by the editorial staff and the printer to eliminate misleading or inaccurate infor-mation, the publisher accepts no responsibility for the consequences of faultful or incorrect information. The authors recognize that the editor and publisher have no responsibility and are indemnified against any liability or claim that may result from the publication of misleading or incorrect data.


SUBSCRIPTION INFORMATION
The Journal is published bimonthly (January, March, May, July, September and November); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.

Subscriptions include six issues per year plus supplements, monographs and all official communications of Meetings, Courses, Symposia and all scientific activities of Gynaecologic Oncology Societies all over the world.

Subscriptions are entered with prepayment only. The annual subscription is $390 US for Institutions, $200 US for Individuals. For airmail add $30, for receipt add $10 US. Single copy prepaid cost $95 US.

Send subscription requests with cheque or credit card payment (Amex - Visa - Diner’s - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. Only US Funds are accepted. No bank transfers.

Claims for missing issues can be honoured up to six months. Changes of address: allow six weeks for all changes to become effec-tive. All communications should include both old and new addresses (with postal codes) – better if accompanied by a mailing label from a recent issue – and should be sent to the printer: La Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580. Claims should be made within six months of publication date.

Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.

Single copies and back issue and volume information is available from the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.

All other business correspondence including orders for offprints and advertising space and any communication and requests should be addressed to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT

 

European Journal of Gynaecological Oncology
www.irog.net


Instructions to Authors

SUBMISSION OF MANUSCRIPTS
Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Sto-rione 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the “Distinguished Expert Series” should be submitted to P. Bösze, Editor-in-Chief of this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest, Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1)
275 2172, E-mail: bosze@axelero.hu

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers’ suggestions.

Manuscripts accepted for publication will be copyedited by the editorial staff for typographical and grammatical mistakes and to guarantee clarity and conciseness.

Publication time will be the shortest possible based on scientific and publishing needs. Manuscripts submitted for publi-cation cannot be returned.

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

After six months no grievances will be accepted regarding published articles.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author’s experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and appli-cation thereof contained in the Journal. Consult the prescribing information before administering any drug.

MANUSCRIPT REQUIREMENTS
The Journal follows the “Uniform requirements for manuscripts submitted to biomedical journals” published in the New England Journal of Medicine 1991, 324, 424-8 and in the British Medical Journal 1991, 302.

Three manuscripts, typed and double spaced should be submitted with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0. Manuscripts without an electronic disk will not be accepted. A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which has never been pub lished or submitted for publication elsewhere. Without a cover letter the publication will not be possible. Name, address and phone/fax numbers of the Corresponding Author, responsible for revision and approval of the proofs, should be indicated. Full-length articles should not exceed 8 printed pages including tables and references.

After the title page (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: Summary (purpose of investiga-tion, methods, results, conclusion - about 150 words), Key words, Content (a 20-word summary), Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement (if any), References, Tables, Legends.

Authors should supply a complete address for reprint requests.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

Authors must give their complete professional identifications and affiliations, including all academic titles and positions.

Letters to the editor should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

Figures: Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author’s name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).

Legends should be typed on a separate page with Arabic numerals corresponding to the illustrations.

Tables should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first cita-tion
in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in Index Medicus. The titles of journals should be abbreviated according to the style used in Index Medicus.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

Articles in Journals: Authors’ surname and initials (if more than six names, give six followed by “et al.”), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue and first page.

Books: Authors’ surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Page.

Acknowledgments
will be limited to appropriate professionals who were contributors to the paper.

PROOFS revised by the editorial staff will be sent to the corresponding author and should be checked and returned within ten days. The corresponding author is responsible for detecting typesetting errors. After this deadline the proofs will be considered approved. Only essential corrections should be made; extensive changes will be charged to the authors.

BUSINESS MATTERS
The Journal has no commercial advertisements.

Authors will be expected to contribute to the printing expenses, tables, figures and postage. For every published article a copy of the Journal will be provided free of charge. Only payments in US dollars will be accepted. No bank transfers.

Reprints should be requested with the form enclosed with the acceptance letter. No free reprints will be supplied.



© By I.R.O.G. CANADA INC. - Publisher - Editorial office 4900 Côte St. Luc - Apt. 212 - Montréal Québec H3W 2H3 (Canada) - Tel. (514) 4893242-4893640 - Fax (514) 4854513 - Printed in Italy by “La Garangola” - Via E. Dalla Costa, 6 - 35129 Padua (Italy) - Responsible Director: Prof. Antonio Onnis M.D. - Authorization of Padua’s Court n. 633 - 28-6-1979
   
European Journal of Gynaecological Oncology - Vol. XXX, n.4, 2009
 
   
CONTENTS  
DISTINGUISHED EXPERT SERIES  
Surveillance of endometrial pathologies, especially for endometrial cancer, of breast cancer patients under tamoxifen treatment 357
F. Neri, T. Maggino - Mestre-Venezia, ITALY
Breast cancer patients treated with tamoxifen need close surveillance for endometrial pathologies during treatment.
 
 
ORIGINAL ARTICLES  
Patterns of care in the initial management of women with ovarian cancer in Ontario 361
L. Elit, S. Schultz, R. Prysbysz, R. Saskin, N. Gunraj, A.S. Wilton, M. Simunovic, D. Urbach - Toronto, CANADA
An evaluation of operative services provided for ovarian cancer patients in Ontario.
 
An attempt at conservative treatment in selected cases of type I endometrial carcinoma (Stage I A/G1) in young women 365
S. Stanosz - Szczecin, POLAND
Conservative treatment of young women diagnosed with Stage I A/G1 endometrial carcinoma could be indicated in some cases. Thorough clinical follow-up with histopathological analysis of D&C material and assessment of sex hormone concentrations in serum is mandatory.
 
Clinicopathological implications of inactivation of RASSF1A in serous epithelial ovarian cancers 370
L. Ma, Q. Guo,Y. Ma, F.R. Liu, X.Y. Shen - Shenyang, CHINA
Promoter hypermethylation of RASSF1A occurs frequently and contributes to gene expression in Chinese primary serious epithelial ovarian cancers.
 
Ovarian carcinoma apparently confined to the ovaries - the accuracy of surgical staging in Israel 375
J. Menczer, A. Chetrit, S. Sadetzki - Tel Hashomer, ISRAEL
An increased awareness of the necessity of accurate surgical staging of tumors apparently confined to the ovaries is needed since it can identify a group of patients who require surgical therapy alone.
 
Perineural invasion in early-stage cervical carcinoma 379
H. Ozan, S. Özuysal, B. Ediz - Bursa, TURKEY
The association between perineural invasion and predictive and prognostic markers in early-stage cervical carcinoma is evaluated.
 
Spleen involvement in women with ovarian cancer 384
G. Cormio, V. Loizzi, C. Carriero, G. Putignano, L. Selvaggi - Bari, ITALY
The prognostic factors of spleen metastases in ovarian cancer were studied.
 
The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia 387

M. Kanis, J.P. Kesterson, S. Lele - Buffalo, NY (USA)
A retrospective analysis of the incidence and severity of palmar-plantar erythrodysesthesia in patients being treated with pegylated liposomal doxorubicin while concurrently taking cod liver oil.

 
Clinicopathological features of primary fallopian tube carcinoma: a single institution experience 389
C.A. Papadimitriou, S. Markaki, E. Lianos, P. Peitsidis, G. Vourli, N. Nikitas, G. Vlachos, A. Rodolakis, A. Antsaklis, M.A. Dimopoulos - Athens, GREECE
Clinical and immunohistochemical characteristics were examined in PFTC. Only early-stage disease and optimal debulking were associated with favorable outcome.
 
Current management of endometrial hyperplasia and endometrial intraepithelial neoplasia (EIN) 396
M. Gültekin, K. Diribas, P. Dursun, A. Ayhan - Ankara, TURKEY
Current management of endometrial hyperplasia is summarized with a brief overview about EIN classification and its clinical importance.
 
The contribution of laparoscopy to the diagnosis of adnexal masses in young and premenopausal women 402
V. Liberis, P. Tsikouras, Ch. Zografos, A. Ammari, V. Dislian, Ch. Iatrou, G. Maroulis - Thessaloniki, GREECE
Laparoscopy plays an important role in the diagnosis of adnexal tumors.
 
Accuracy of intraoperative frozen section during laparoscopic management of early endometrial cancer 408
E. Kucera, H. Václav, T. Radovan, M. Otcenásek, J. Drahonovsky, J. Feyereisl - Prague, CZECH REPUBLIC
In this retrospective study the significance of frozen section biopsies in surgical treatment provided for endometrial cancer was evaluated.
 
Assessment of the predictivity of preoperative serum CA 125 in the differential diagnosis of uterine leiomyoma and uterine sarcoma in the Turkish female population 412
N. Yilmaz, I. Sahin, S. Kilic, E. Ozgu, T. Gungor, U. Bilge - Ankara, TURKEY
Preoperative serum CA 125 levels were not significant in the differential diagnosis between uterine leiomyoma and uterine sarcoma.
 
Uterine cervical neoplasia prevention in Parque Indigena do Xingu 415
N.M. de Góis Speck, É.R. Pereira, M. Schaper, F.K. Tso, V.G. de Freitas, J.C.L. Ribalta - São Paulo, SP (BRAZIL)
Results of preventive screening, diagnosis and treatment applied to native Parque Indigena do Xingu women are seen.
 
The role of immunonutrition in gynecologic oncologic surgery 418
J.B. Çelik, K. Gezginç, K. Özçelik, Ç. Çelik - Konya, TURKEY
Immunonutrition during the perioperative period is required to prevent infectious complications and improve clinical outcome.
 
Analysis of the results and long-term follow-up of second-look laparotomy in advanced ovarian cancer 422
S. Sawicki, D. Wydra, J. Kobierski, T. Milczek, J. Emerich - Gdansk, POLAND
The study presents the results of 171 second-look laparotomies and compares survival of patients with advanced ovarian cancer depending on SLL results.
 
Peritoneal tuberculosis mimicking peritoneal carcinomatosis 426
H. Ozan, K. Özerkan, A. Orhan - Bursa, TURKEY
Distinction of peritoneal tuberculosis from peritoneal carcinomatosis is discussed.
 
Estrogen receptor a (ER-α) gene polymorphism in patients from the Lodz region of Poland with sporadic endometrial cancer 431
A. Sobczuk, B. Smolarz, H. Romanowicz-Makowska, T. Pertyn ´ski - Lodz, POLAND
Polymorphism of the ER-α gene does not appear to be directly associated with appearance and development of endometrial cancer.
 
 
Breif Communication  
Valid generic substitution of carboplatin for patients with gynecological cancer 435
A. Imai, N. Ito - Yanagido, JAPAN
The validity of generic carboplatin in patients affected by gynecological cancer is examined.
 
 
CASE REPORTS  
Synchronous endometrioid carcinoma of the uterine corpus and ovary. A case report and review of the literature 437
X. Grammatoglou, E. Skafida, C. Glava, E. Katsamagkou, E. Delliou, Th. Vasilakaki - Piraeus, GREECE
The case of a 52-year-old woman with synchronous endometrioid carcinoma of the uterine corpus and ovary is presented.
 
Primary ovarian leiomyosarcoma associated with Brenner tumor 440
Y. Li, L.D. Feng, A.G. Ma, H.J. Lu - Shanghai, CHINA
A case of a rare tumor with interesting immunohistochemical findings is described.
 
Paratubal endometrioid cystadenocarcinoma: case report and review 443
C. Vaysse, J. Capdet, E. Mery, D. Querleu - Cedex, FRANCE
A rare case of paratubal invasive endometrioid adenocarcinoma that has been managed according to the recommendations of ovarian cancer is presented.
 
Large retroperitoneal schwannoma mimicking ovarian carcinoma: case report and literature review 446
T. Aran, S. Guven, S. Gocer, S. Ersoz, H. Bozkaya - Trabzon, TURKEY
Schwannomas are rarely located in the retroperitoneum and can be misdiagnosed as an adnexal mass or ovarian carcinoma even in young woman.
 
Prolonged clinical benefit from platinum-based chemotherapy in a patient with metastatic triple negative breast cancer 449
M. Krockenberger, J.B. Engel, S. Häusler, J. Dietl, A. Honig - Würzburg, GERMANY
Further evidence for the clinical benefits of platinum-based chemotherapy in early and advanced triple negative breast cancers.
 
Broad ligament leiomyosarcoma in a premenopausal nulliparous woman: case report and review of the literature 452
S. Papachatzopoulos, T.D. Theodoridis, M. Zafrakas, P. Nikolakopoulos, E. Molibas - Thessaloniki, GREECE
A rare case of broad ligament leiomyosarcoma in a premenopausal nulliparous woman is presented with a review of the literature.
 
Umbilical metastasis of serous component as a first sign of mixed type epithelial ovarian cancer 455
S. Kurt, H. Camuzcuoglu, A. Camuzcuoglu, N. Dicle, S. Tinar - Sanliurfa, TURKEY
The first reported case of umbilical metastasis of the serous component as a first sign of mixed type epithelial ovarian cancer.
 
Paget’s disease of the vulva in a patient with scleroderma and underlying adenocarcinoma: case report 458
T. Dimitroulas, L. Settas - Thessaloniki, GREECE
A case of a 71-year-old woman with scleroderma and Paget’s disease of the vulva is presented.
 
Vulvar neoplasm and reconstruction of a lesion with a vertical rectus abdominis myocutaneous flap: case report 460
S. Petkovic, J. Jeremic, K. Jeremic, Z. Nikolic, A. Stefanovic, M. Maksimovic - Belgrade, SERBIA
Radical vulvectomy with bilateral groin dissection and reconstruction with a large flap is still the standard treatment for patients affected by advanced vulvar cancer.